ClinicalTrials.gg
CompletedNCT01353469Insuman-C25-CNUpdated Feb 27, 2013

Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy

A Phase 3 interventional study of Insulin human/Insuman Comb 25 (HR1799) and Insulin human/Novolin® 30R in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 23 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-02-27.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
485
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 186 studies in Diabetes Mellitus, Type 2 by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Sanofi.

Enrollment
52nd of 178
485 · median 334
Started
2011
with 5 others
Phase 3
80 of 186
none open now
Registered
100th of 186
by date

Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 52nd largest by enrollment of the 178 interventional ones that give a count, is one of 6 that started in 2011, is one of 80 in phase 3, and was the 100th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 186 studies in Diabetes Mellitus, Type 2 by Sanofi is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Diabetes Mellitus, Type 2 by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To compare the efficacy of Insuman Comb 25 versus Novolin® 30R on HbA1c reduction during a 24-week treatment period in patients with type 2 diabetes mellitus.

Secondary Objectives:

  • To assess the effects of Insuman Comb 25 versus Novolin® 30R in patients with type 2 diabetes mellitus on fasting plasma glucose (FPG)
  • To assess the safety and tolerability of Insuman Comb 25 versus Novolin® 30R in patients with type 2 diabetes mellitus
Read the detailed description

The study duration per patient is about 27 weeks (up to 2 weeks screening + 24 weeks open-label treatment + 1 week follow-up).

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus patients, as defined by World Health Organization (WHO), diagnosed for at least 1 year at the time of screening visit who are under premix insulin therapy, with or without oral anti-diabetic drug (OAD)
  • Signed written

Exclusion criteria

Exclusion criteria:

  • \<7% or HbA1c >10% at screening
  • No self-monitoring of blood glucose within 3 months prior to screening visit
  • Premix insulin treatment for less than 3 months. Insulins other than premix insulin treatment within 3 months prior to screening visit
  • In case of treatment with OAD, treatment with a stable OAD dose and regimen for less than 3 months prior to screening visit

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
485 participants (actual)

Study arms

  • Experimental
    Insuman Comb 25

    Insuman Comb 25 will be self-injected subcutaneously twice daily 30-45 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline.

    Drug: Insulin human/Insuman Comb 25 (HR1799)

  • Active comparator
    Novolin® 30R

    Novolin® 30R will be self-injected subcutaneously twice daily within 30 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline and the package insert of Novolin® 30R

    Drug: Insulin human/Novolin® 30R

Interventions

  • DrugInsulin human/Insuman Comb 25 (HR1799)

    Pharmaceutical form:Suspension Route of administration: Subcutaneous

  • DrugInsulin human/Novolin® 30R

    Pharmaceutical form:Suspension Route of administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Change in HbA1c from baseline to the end of treatment

    Time frame: 24 weeks

Secondary outcomes

  1. Change in fasting plasma glucose from baseline to the end of treatment

    Time frame: 24 weeks

07

Study locations

23 sites
  • Investigational Site Number 156024
    Beijing, 100088, China
  • Investigational Site Number 156010
    Beijing, 100730, China
  • Investigational Site Number 156001
    Beijing, 100853, China
  • Investigational Site Number 156033
    Changchun, 130011, China
  • Investigational Site Number 156017
    Changchun, 130041, China
  • Investigational Site Number 156005
    Changsha, 410008, China
  • Investigational Site Number 156021
    Chengdu, 610072, China
  • Investigational Site Number 156006
    Chongqing, 400016, China
  • Investigational Site Number 156032
    Hangzhou, 310013, China
  • Investigational Site Number 156007
    Harbin, 150001, China
  • Investigational Site Number 156020
    Hefei, 230001, China
  • Investigational Site Number 156016
    Nanjing, 210006, China
  • Investigational Site Number 156018
    Nanjing, 210011, China
  • Investigational Site Number 156002
    Shanghai, 200003, China
  • Investigational Site Number 156023
    Shanghai, 200040, China
  • Investigational Site Number 156031
    Shanghai, 200062, China
  • Investigational Site Number 156004
    Shanghai, 200065, China
  • Investigational Site Number 156027
    Shenyang, 110022, China
  • Investigational Site Number 156029
    Suzhou, 215004, China
  • Investigational Site Number 156025
    Tianjin, 300052, China
  • Investigational Site Number 156003
    Wuhan, 430022, China
  • Investigational Site Number 156008
    Xi'An, 710032, China
  • Investigational Site Number 156009
    Xi'An, 710061, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2011
First posted
May 13, 2011
Start
May 2011
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Last update
Feb 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01353469
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 13, 2011
Start date
May 2011
Primary completion
Nov 2012
Completion
Nov 2012
Last update
Feb 27, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion